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Introduction {#sec1}
============

CD4+ T cells are key players of the adaptive immune system. Upon antigenic stimulation, the naive CD4+ T (T helper precursor \[Thp\]) cells polarize into distinct T helper (\[Th\], i.e., Th1, Th2, Th9, and Th17) and regulatory T (Treg) cells ([@bib59]). Although their primary function is to provide protective immunity against various intracellular and extracellular pathogens, they can also exhibit inappropriate responses in inflammatory and autoimmune diseases ([@bib49], [@bib33], [@bib21]). Th17 cells are a subset of Th cells that are characterized by the expression of their key transcription factors, STAT3 and RORC and the chemokine receptor CCR6 as well as by the secretion of signature cytokines interleukin (IL)-17A and IL-17F. They are critical in combating fungal infections and contribute to the pathogenesis of several inflammatory and autoimmune diseases and various cancers ([@bib36], [@bib7], [@bib14]). The characterization of the molecular mechanisms regulating the differentiation and function of the Th17 cells is therefore of great interest for research into the etiology and treatment of these diseases.

Until now, our understanding of the proteins that are most important in Th17 differentiation and function in both human and mouse has originated from transcriptional profiling analyses ([@bib20], [@bib81], [@bib92], [@bib32]). These analyses have identified a number of genes that now serve as key markers for Th17 cells. However, this approach is limited as some transcriptional changes are not necessarily reflected at the proteome level ([@bib85]). For example, several post-transcriptional and post-translational mechanisms modulate the stability and activity of many of the proteins involved ([@bib45]). Characterization of the cellular proteome of Th17 cells enables the discovery of unique protein signatures and regulated cellular pathways that drive Th17 cell development and function. A better understanding of the proteome during the differentiation process facilitates the rational design of drugs targeting Th17-mediated inflammatory and autoimmune diseases.

Mass-spectrometry (MS)-based proteomic analysis is a powerful tool for comprehensively profiling the proteome in different cellular systems, including T cells ([@bib22], [@bib37]). Previously, MS-based proteomic analysis of differentiating T cells focused mainly on classical Th1 and Th2 cells using *in vitro* differentiation systems ([@bib46], [@bib64]). In addition, addressing disease-related traits, the proteomic profiles were compared for *in vivo* differentiated Th1 and Th1/Th17 cell clones isolated from biopsies of gut samples from patients with Crohn disease ([@bib65]). Recently, a number of studies identified a distinct set of differentially regulated proteins when comparing the proteomes of CD4+CD25+ Foxp3 expressing natural Treg cells and induced Treg (iTreg) with CD4+ conventional T cells both in human and mouse ([@bib42], [@bib25], [@bib23], [@bib70]). Most recently, a study reported Th17 proteome profiles in mouse ([@bib53]). Although studies of the molecular profiles and mechanisms governing different Th and Treg cell differentiation have been mostly performed in mouse, previous reports that have compared the transcriptomic profiles of human and mouse have revealed significant differences between the two species ([@bib72], [@bib85]). As the findings from studies based on mouse disease models often cannot be replicated in humans, studies in humans are critical ([@bib51], [@bib47]).

In the current study, we utilized a label-free MS-based approach to build a quantitative dataset on the cellular proteome of naive CD4+ human T cells, CD3/CD28 activated T (Th0) cells, and Th17 cells at 24 and 72 hr after the initiation of polarization. Statistical analysis of the data revealed a Th17-cell-specific proteome signature with a number of proteins regulated during Th17 cell differentiation already at the early stage of the differentiation process. Moreover, selected proteins with previously known and unknown Th17-related functions were validated in additional samples by distinct methods to confirm the results. Furthermore, the proteomics and transcriptomics data generated in this study were compared to determine the degree of concordance between these two. Notably, a comparison of our human Th17-regulated proteome with the mouse Th17 proteome demonstrated poor overlap between the two species. Last, using the RNA interference (RNAi) approach, we demonstrated SATB1 as a negative regulator of human Th17 cell differentiation process in contrast to mouse, where it positively regulates Th17 cell differentiation ([@bib20]). This study illustrates the global protein landscape and the mRNA-protein associations during early human Th17 cell differentiation. This dataset provides a valuable resource of candidate proteins potentially regulating the differentiation and functions of Th17 cells in humans. Further investigation on these candidate proteins might lead to the rational design of targets with therapeutic potential for modulating Th17-mediated immune responses in humans.

Results {#sec2}
=======

Quantitative Proteomic Analysis during Initiation of Human Th17 Differentiation {#sec2.1}
-------------------------------------------------------------------------------

We investigated the quantitative changes in the cellular proteome of human naive Th cells during the early stages of human Th17 cell differentiation using shotgun label-free quantitative (LFQ) proteomics. Naive CD4+ T cells isolated from the human umbilical cord blood were either activated by T cell receptor (TCR) cross-linking with CD3 and CD28 antibodies (Th0 cells) or polarized with a cytokine cocktail of IL-1β, TGF-β, and IL-6 in combination with TCR/CD28 cross-linking to initiate Th17 cell differentiation. Polarization was monitored by the expression of Th17 cell marker genes, including CCR6, IL-17A, and IL-17F, and the master transcription factor RORC ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D). The Thp cell sample and the Th0 and Th17 cell samples at 24- and 72-hr time points post-initiation of polarization were collected from five individual donors. To rule out the possibility of polarization toward interferon (IFN)-γ-expressing pathogenic Th17 cells, expression of the IFN-γ cytokine was monitored in three separate Th17 cultures prepared in a similar manner ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). The samples were prepared using the filter-aided sample preparation protocol and analyzed in triplicate by liquid chromatography-tandem MS (LC-MS/MS) ([Figure S1](#mmc1){ref-type="supplementary-material"}G).

Using the label-free MS approach, we identified more than 5,600 unique proteins among the Thp, Th0, and Th17 cell subsets ([Table S1](#mmc2){ref-type="supplementary-material"}). Samples in the normalized data clustered according to the biological replicates and cell lineages indicating successful normalization, good reproducibility, and general good quality of the data ([Figure S2](#mmc1){ref-type="supplementary-material"}). The proportion of missing values in the samples was low in general (\<7%), being largest in the Thp cells (∼4.4%--6.1%).

Furthermore, a considerable number of proteins were detected as differentially expressed (DE) between the different cell subsets. On comparing Th0 and Thp cells, 2,050 and 3,470 proteins were detected as DE (false discovery rate \[FDR\] ≤ 0.05) at 24 and 72 hr after the onset of the polarization, respectively ([Figure 1](#fig1){ref-type="fig"}A; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). Similarly, on comparing Th17 and Thp cells, 2,288 proteins were DE at 24 hr and 3,271 at 72 hr, respectively. Among the proteins DE in response to TCR activation (Th0 versus Thp), 935 and 1,674 proteins were downregulated and 1,115 and 1,796 proteins were upregulated in Th0 at 24 and 72 hr, respectively. Likewise, in response to combined TCR activation and Th17-polarizing cytokines (Th17 versus Thp), 1,180 and 1,572 proteins were downregulated and 1,108 and 1,699 proteins were upregulated in Th17 cells at 24 and 72 hr, respectively. As expected, owing to the similarity of the cells at the early stage of Th17 polarization, the differential expression analysis between Th17 and Th0 cells revealed only 148 and 175 proteins differentially regulated at 24 and 72 hr, respectively ([Figure 1](#fig1){ref-type="fig"}A; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). Among the proteins that were DE in the Th17-polarizing conditions in a time-point-specific fashion (i.e., detected as DE only at either time points), 60 and 92 proteins were upregulated and 56 and 51 proteins were downregulated at 24 and 72 hr, respectively ([Figures 1](#fig1){ref-type="fig"}B and 1C). Interestingly, only a small number of DE proteins were found to be common at both time points ([Figure 1](#fig1){ref-type="fig"}D), suggesting that the differentially regulated proteins have a stage-specific function in driving Th17 differentiation.Figure 1The Differentially Expressed (DE) Proteins in the Proteomics Data(A--D) (A) The number of up- and downregulated proteins between Th0 and Thp cells, Th17 and Thp cells, and Th17 and Th0 cells at 24 and 72 hr. At 72 hr, the number of proteins detected up- or downregulated already at 24 hr is shown in darker color. The *Z* score standardized expressions of the DE proteins between Th17 and Th0 unique to 24 hr (B), unique to 72 hr (C), and common to both time points (24 and 72 hr) (D). Black color in the heatmaps stands for undetected/missing value.

Among the proteins detected as DE in this data, several are previously known to be preferentially expressed and regulated during Th17 differentiation. These included AHR ([@bib83]), JUNB ([@bib17]), FOSL2 ([@bib20]), RBPJ ([@bib52]), SIRT1 ([@bib43]), REL ([@bib19]), CCL20 ([@bib27]), and TNFSF8 ([@bib76]). Notably, our analysis also identified several other proteins (e.g., UHRF1, GK, ICAM1, KDSR, ATF3, IL4IT, APOD, VIM, PALLD, PTGFRN, and KDM6A) differentially upregulated with unexplored/unknown functions in Th17 cells ([Figures 1](#fig1){ref-type="fig"}B and 1C). Interestingly, proteins related to antiviral pathways (e.g., IRF7, MX1, OAS, OAS31, and OASL) were upregulated, suggesting the role of IFN signaling in driving Th17 differentiation. We observed the upregulation of the ADP ribosyl transferase poly (ADP-ribose) polymerase (PARP) superfamily proteins, including PARP-9, PARP-10, and PAPR-14, together with the RNA helicase DEAD-box proteins, such as DDX58 and DDX60. PARP-14 is highly expressed and positively regulated during the development of Th17 and T helper follicular cells in mouse by modulating the phosphorylation of STAT3, a key transcriptional regulator of both ([@bib50]). Several negative regulators of Th17 cell development ([@bib20], [@bib92]), including IRF8, ETS1, STAT4, FYN, CASP1, and SMAD3, were significantly downregulated in differentiating Th17 cells. Interestingly, among the downregulated proteins, we also observed several proteins with unexplored function in Th17 biology including ELF1, IL16, BTLA, LAIR1, UHRF1, ANXA1, NDFIP1, and NDFIP2.

Functional Analysis of the Th17 DE Proteins {#sec2.2}
-------------------------------------------

We examined the enrichment of Gene Ontology (GO) annotations for biological processes among the DE proteins over both time points. The GO analysis revealed significant (FDR ≤0.05) enrichment of approximately 300 biological processes ([Table S3](#mmc4){ref-type="supplementary-material"}). The enriched processes included a number of important immunological processes, such as regulation of immune system development, immune system processes, response to external stimulus, cell surface receptor signaling pathways, cytokine production, cytokine-mediated signaling pathways, positive regulation of cellular metabolic processes, T cell activation, and lymphocyte differentiation ([Figure 2](#fig2){ref-type="fig"}A; [Table S3](#mmc4){ref-type="supplementary-material"}).Figure 2Enriched GO Biological Processes for the Proteins Differentially Expressed between Th17 and Th0 in the Proteomics Data(A) The proportions of DE proteins for the 15 chosen representative GO biological processes out of all the annotated DE proteins.(B) The averaged standardized expressions of 10 of the most upregulated and 10 of the most downregulated proteins in each of the three chosen representative GO biological processes. The GO analysis was performed using DAVID over both time points. The detected proteome was used as a reference background.

We observed that proteins related to lipid metabolic process were highly regulated in Th17 cells, which is in agreement with the recent studies showing the role of fatty acid metabolism in regulating Th17 cell differentiation and function ([Figure 2](#fig2){ref-type="fig"}B) ([@bib9], [@bib68]). Known proteins of interest, such as VDR ([@bib18]), are involved in lipid metabolism and have previously been linked to Th17 differentiation. MSMO1 and CYP51A1 are both also involved in lipid metabolism and have been reported to regulate RORC expression and the pathogenic activity of Th17 cells ([@bib68]). Our analysis additionally identified a number of other proteins related to lipid metabolism signaling whose functions in regulating Th17 differentiation have not yet been defined ([Table S3](#mmc4){ref-type="supplementary-material"}). As expected, we observed a number of proteins that were common to the immune system process and response to cytokines, including CD274 (PD-L1), CCL20, IFIT1, IRF7, and ETS1 ([Figure 2](#fig2){ref-type="fig"}B). Notably, proteins induced in response to IFN and antiviral pathways were highly enriched for the GO term "response to cytokine," including OASL, ISG20, IRF7, and IFN-induced protein with tetratricopeptide repeat (IFIT) family proteins.

The Ingenuity Pathways Analysis (IPA; <https://www.qiagenbioinformatics.com>) was used to assign the molecular functional types and cellular locations of the proteins DE between Th17 and Th0 cells ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B; [Table S3](#mmc4){ref-type="supplementary-material"}). The IPA analysis revealed distinct molecular function types for the Th17-regulated proteins, including enzymes (∼23%), transcription regulators (∼12%), transporters and kinases (5% each), transmembrane receptors (4.6%), peptidases and cytokines (3.5% each), phosphatases (2.5%), and G-protein receptors (1.1%). In addition, a small fraction of the Th17 DE proteins was recognized as growth factors, ligand-dependent nuclear receptors, ion channels, and translation regulators (\<1% each). A major fraction of the Th17 DE proteins (\>37%) were classified as others owing to their undefined functions ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Moreover, the IPA analysis for cellular compartment revealed four major cell locations for the proteins DE between Th17 and Th0 cells, including the cytoplasm (45.4%), nucleus (23.8%), plasma membrane (19.9%), and extracellular space (8.2%), with only 2.8% of the DE proteins belonging to an undefined (other) cell location ([Figure S3](#mmc1){ref-type="supplementary-material"}B; [Table S3](#mmc4){ref-type="supplementary-material"}). Thus the enrichment of proteins assigned to various molecular functional types and their location at different cellular compartments indicate the involvement of distinct signaling pathways and transcriptional mechanisms during differentiation of Th17 cells. In conclusion, our analysis identified proteins from almost all the functional types and cellular compartments, providing a valuable resource for further investigation of candidate proteins potentially regulating the differentiation and function of Th17 cells in humans.

An Interaction Network for the DE Proteins during Early Th17 Cell Polarization {#sec2.3}
------------------------------------------------------------------------------

To understand the relationships between proteins identified in our data, we performed a protein-protein interaction network analysis for the proteins DE in Th17 cells at both time points by mining the STRING database ([@bib78]). Of the 291 unique proteins detected as DE between Th17 and Th0, 146 were found to have known experimental or predicted interactions ([Figure 3](#fig3){ref-type="fig"}). Altogether 443 interactions between the 146 proteins were detected. To further examine the possible functional elements among the interacting proteins, we identified clusters based on the interactions in the resulting network ([Table S4](#mmc5){ref-type="supplementary-material"}). This yielded altogether 15 clusters, with seven of the clusters having four or more interacting proteins. The average interaction score between the cluster members in the identified clusters was high (0.77--0.93, range 0--1). To infer the functional relevance of the identified clusters, we examined the prevalence of the enriched GO biological processes within the seven clusters ([Table S3](#mmc4){ref-type="supplementary-material"}). To further complement our network analysis, we included the changes in expression between Th17 and Th0 for the interacting proteins. The functional interaction analysis identified cluster 1 as the largest cluster with altogether 78 interconnected proteins related to distinct GO biological processes, including immune responses, positive regulation of cellular metabolic processes, and response to organic substances as the top three representative GO biological processes ([Figure 3](#fig3){ref-type="fig"}A). A large proportion of the proteins included in cluster 1 were either upregulated at 24 or 72 hr or downregulated at 24 hr, whereas only a small portion seemed to be downregulated at 72 hr. In addition, all the proteins of clusters 2 and 3 were related to lipid metabolic processes ([Figure 3](#fig3){ref-type="fig"}A). Furthermore, all proteins included in clusters 2 and 3 were found to be differentially regulated only at 24 hr (except for ACSL4, which was upregulated also at 72 hr).Figure 3The Interaction Network among the DE Proteins between Th17 and Th0The network is based on all high-confidence experimental and predicted interactions from the STRING database.(A) The network of protein-protein interactions from the DE proteins between Th17 and Th0 over both time points. The representative significant GO biological processes and cluster identities are shown only for clusters 1--7 (clusters sized \>3).(B) Cluster 1 divided into sub-clusters and the enriched pathways identified using the ReactomeFIViz Cytoscape plug-in. The letter in parentheses after each pathway name denotes the source of the annotation: R, Reactome; K, KEGG; N, NCI PID. The edges in the networks were bundled for a clearer representation. The logarithmic fold change between Th17 and Th0 at 24 hr (node inner circles) and at 72 hr (node outer circles) was implemented as continuous color mapping. For a clearer representation, the logarithmic fold changes are truncated to a range of −2 to 2.

Furthermore, to gain insight into the biological implication of expression changes in cluster 1, we analyzed the proteins in the context of biological pathways. A close examination identified three distinct functional sub-clusters within cluster 1 that were further called for functional enrichment of biological pathways ([Figure 3](#fig3){ref-type="fig"}B). The proteins in sub-clusters 1 and 3 were enriched for biological pathways involving signaling by TGF-β receptor complex, IL-6-mediated signaling events, signaling by interleukins, Th1 and Th2 cell differentiation, and the JAK-STAT signaling pathway. Interestingly, we observed a number of proteins in these two sub-clusters that are known modulators of Th17 cell differentiation, including CDK6, RUNX1, JUNB, SIRT1, RBPJ, TNF, SLAMF1, and FAS (positive regulators of Th17 cell differentiation) and FOSL2, SMAD3, ETS1, STAT4, and FYN (negative regulators of Th17 cell differentiation). Noticeably, the majority of proteins in sub-cluster 2 were upregulated in Th17 condition at 72 hr and enriched for antiviral immune pathways including IFN-α/β signaling, RIG-I-like receptor signaling pathway, and NOD-like receptor pathway ([Figure 3](#fig3){ref-type="fig"}B). The enrichment of antiviral proteins in the network at this early stage of differentiation is interesting because they are known to negatively modulate Th17 differentiation ([@bib63], [@bib91]). However, the expression of IRF-8 was downregulated in Th17 cells at 24 hr. IRF-8 is a known suppressor of Th17 cell differentiation in mouse ([@bib60]). Further studies are needed to characterize the role of proteins related to antiviral pathway in human Th17 cell differentiation. To summarize, we identified protein-protein interaction networks of the proteins related to distinct biological processes and cellular pathways indicating their coordinated regulation during early Th17 cell differentiation program.

Validation of Mass-Spectrometry-Identified Th17 DE Proteins {#sec2.4}
-----------------------------------------------------------

MS-based global proteomics approaches for protein identification rely on probability algorithms and benefit from further validation by targeted MS or other methods, such as immunoblotting or flow cytometry. We used all these three means to validate the expression profiles of selected candidate proteins. Results using western blot and flow cytometry analysis are shown in [Figures 4](#fig4){ref-type="fig"}A, 4B, and [S4](#mmc1){ref-type="supplementary-material"}). We have previously shown the changes in protein expression of BASP1 ([Figure 4](#fig4){ref-type="fig"}A), LMNA ([Figure 4](#fig4){ref-type="fig"}A), and ATP1B1 (in [Figure 4](#fig4){ref-type="fig"}D) in Th17 cells, and these were used here as marker genes that further confirmed consistency between our current and previous results ([@bib81]). Western blot analysis for the selected Th17 upregulated proteins (JUNB, SIRT1, CTNNA1, FAS, VIM, and IRF7) and downregulated proteins (SATB1, SMAD3, STAT4, and ETS1) showed consistent results with the proteomic analysis ([Figures 4](#fig4){ref-type="fig"}A, 4B, and [S4](#mmc1){ref-type="supplementary-material"}). Using flow cytometry, we also validated the expression of OASL and ATF3 at 72 hr after the initiation of Th17 cell polarization. Again, the results were in agreement with the proteome data showing Th17-specific increased expression of OASL and ATF3 ([Figure 4](#fig4){ref-type="fig"}C). The function of BASP1, LMNA, CTNNA1, OASL, ATF3, and VIM in modulating Th17 cell differentiation and functions remains to be studied.Figure 4Validation of the Mass-Spectrometry (MS)-Identified Proteins Using Immunoblotting, Flow Cytometry, and Targeted Mass-Spectrometry-Based Selected Reaction Monitoring (SRM) Analysis(A and B) Immunoblot validations of MS identified up- or downregulated proteins with known and unknown Th17-related function. Blots show the protein extracts from the Th0 and Th17 cells at 24 and 72 hr. A representative blot from three biological replicates is shown.(C) Flow cytometry validations of OASL and ATF3 detected as differentially upregulated in Th17 cells by MS analysis. A representative histogram image from Th17 (red), Th0 (black), and isotype control (gray) as well as the mean of four biological replicates are shown. Error bars represent standard deviation values across biological replicates (n=4; \*p\<0.05 for Th0 versus Th17; two-tailed t-test analysis).(D) Confirmation of the protein expression of six proteomics candidates, ATP1B1, PALLD, ACSL4, FHOD1, SMTN, and RDX, using targeted SRM analysis. The SRM data is from four biological replicates and represented as the mean values +/- 95% confidence interval. (n = 4; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.0001, for Th17 versus Th0).

In addition, we confirmed the expression of five additional candidates with unknown function in Th17 biology, namely, PALLD, ACSL4, SMTN, RDX, and FHOD1 in addition to ATP1B1 using a targeted MS-based selected reaction monitoring analysis ([Figure 4](#fig4){ref-type="fig"}D). Long-chain acyl-CoA synthetase 4 (ACSL4) belongs to the class of enzymes that catalyses addition of a coenzyme-A (CoA) group to free long-chain fatty acids, specifically arachidonic acid and eicosapentaenoic acid, and converts them into acyl-CoA forms ([@bib41]). As recent studies have advocated the role of lipid metabolism in regulating Th17 cell differentiation and function ([@bib9], [@bib86], [@bib75], [@bib93]), it will be of interest to investigate how ACSL4 regulates Th17 cell function. The formin-homology-domain-containing protein FHOD, radixin (RDX), and smoothelin (SMTN) are cytoskeleton proteins that regulate cell migration and contraction ([@bib57], [@bib71]). Radixin is a part of membrane-associated ERM (ezrin-radixin-moesin) family proteins that plays a key role in activation and T cell homeostasis by regulating cell adhesion, migration, and mobility and promotes T cell-antigen-presenting cell interaction ([@bib28], [@bib55]). The role of these proteins in regulating Th17 cell functions remains to be established. To summarize, we confirmed the protein expression changes for the selected proteins detected by proteomics analysis by alternative methods in separate, independent biological replicates. These candidates provide interesting targets for further functional studies to reveal unknown mechanisms regulating Th17 cell differentiation and function.

Comparison of the Transcriptome and Proteome of the Differentiating Th17 Cells {#sec2.5}
------------------------------------------------------------------------------

To find out the degree of concordance between protein and corresponding mRNA expression, we compared proteome and RNA sequencing (RNA-seq) datasets from the same human Th0 and Th17 cells at the 72-hr time point. Altogether 12,400 transcripts were detected from RNA-seq data ([Figure 5](#fig5){ref-type="fig"}A; [Table S5](#mmc6){ref-type="supplementary-material"}). Proteomics and transcriptomics showed high degree of overlap as there were transcripts corresponding to 95.5% (5,661) of the 5,923 proteins detected by LC-MS ([Table S5](#mmc6){ref-type="supplementary-material"}). Approximately half (54.3%, 6,739) of the protein-coding genes detected in RNA-seq data was not detected in the corresponding proteomics data. This is consistent with recent studies on other types of human T cells showing that approximately 35%--60% of the protein-coding genes detected by RNA-seq data were not detected in the corresponding proteomic data ([@bib23], [@bib70]). To gain further insight into the Th17-cell-specific protein expression changes and their relative mRNA expression changes, we examined the overlap of differentially regulated proteins with the mRNA transcriptome data. Of total 191 differentially regulated proteins, 186 were detected in transcriptomics data, among which 172 were DE (Th17 versus Th0). Altogether 262 proteins were uniquely detected in proteomics data, of which 257 proteins were not differentially regulated between Th0 and Th17 cells. Three proteins were DE in proteomics but not detected in transcriptomics data, and two proteins were detected only in one cell type in proteomics data, but not detected in transcriptomics data ([Figure 5](#fig5){ref-type="fig"}A; [Table S5](#mmc6){ref-type="supplementary-material"}). The Pearson correlation coefficient analysis of the logarithmic fold changes showed a good correlation for all the common detections between proteomics and transcriptomics (0.519, p value \< 0.001, n = 5,661). Importantly, an improved correlation was observed for the common DE proteins and DE transcripts (0.825, p \< 0.001, n = 154). As anticipated the DE findings unique to proteomics among the common detection showed a poor correlation (0.233, p = 0.35, n = 18) ([Figure 5](#fig5){ref-type="fig"}B, [Table S5](#mmc6){ref-type="supplementary-material"}).Figure 5Correspondence of the Differentially Regulated Proteins between Th17 and Th0 and the Transcriptomics Data at 72 hr(A) Venn diagram demonstrating the total number of common and unique detections and the total number of differentially regulated and differentially expressed (DE) proteins detected uniquely in the proteomics and commonly with the transcriptomics data. Differentially regulated proteins refer to those proteins detected as differentially expressed or detected only in one condition.(B--E) (B) The logarithmic fold changes (logFC) of the all the common detections in proteomics and transcriptomics. The differentially expressed (DE) proteins detected as DE also in transcriptomics are marked with black and those uniquely DE in proteomics are marked with red. The Pearson correlation coefficient over the logFCs over all the common detections was 0.519 (p value \< 0.001, n = 5,661), over the common DE findings 0.825 (p\<0.001, n = 154), and over the DE findings unique to proteomics among the common detections 0.233 (p = 0.35, n = 18). The *Z* score standardized expression levels of the DE proteins and the corresponding DE transcripts between Th17 and Th0 (C) upregulated in Th17 in both datasets, (D) downregulated in Th17 in both datasets, and (E) divergently regulated between datasets.(F) The *Z* score standardized expression levels of the DE proteins not detected as DE in transcriptomics. Black color in the heatmaps stands for undetected/missing value.

For a more comprehensive comparison of the proteomics and transcriptomics data, we focused our analyses on the common differentially regulated proteins (163 proteins) either detected only in one condition (nine proteins; detected either in Th0 or Th17 condition) or DE proteins (154 proteins) having corresponding DE transcripts between Th17 and Th0 ([Figures 5](#fig5){ref-type="fig"}C--5E). Noticeably, among the 163 differentially regulated proteins with corresponding detected transcripts, a large majority (93.2%) was changed in a similar fashion between mRNA and protein levels ([Figures 5](#fig5){ref-type="fig"}C and 5D; [Table S5](#mmc6){ref-type="supplementary-material"}). Among these, 107 proteins and their corresponding mRNAs were consistently upregulated, including RBPJ, RUNX1, CCL20, BASP1, ATP1B1, and LMNA, and 45 proteins and their corresponding mRNAs were consistently downregulated, such as SMAD3, SATB1, ETS1, IL2RG, and Nedd4-family-interacting protein 1 (Ndfip1). However, 11 molecules showed opposite expression changes between mRNA and protein expression for both up- and downregulated genes at both time points ([Figure 5](#fig5){ref-type="fig"}E). This anti-correlation profile of proteins and mRNA observed in our data was also seen in another study comparing human iTreg transcriptome and proteome ([@bib70]). Of note, 21 proteins DE between Th17 and Th0 cells were not detected as DE in the transcriptome data ([Figure 5](#fig5){ref-type="fig"}F and [Table S5](#mmc6){ref-type="supplementary-material"}), suggesting that they may be post-transcriptionally regulated. Furthermore, the transcripts corresponding to CCSMST1, ACTBL2, and APOA2 proteins were not detected in transcriptomics data across all replicates. Further validation and evaluation of the differences in the expression profiles of these proteins with available good-quality antibodies such as GOLIM4, CNTRL, CASP1, RAD18, CNBP, NDFIP2, and ITM2B are required to understand the mechanisms responsible for their regulation. Thus our comparative analysis of the transcriptome and the proteome showed mostly similar, and also opposite expression, changes in the mRNA-protein levels, consistent with dynamic regulation of mRNA and protein expression. Moreover, our analysis highlighted the importance of proteomic analysis in complementing measurements on the transcriptome level.

Comparison of the Human and Mouse Proteomes during Early Th17 Cell Polarization {#sec2.6}
-------------------------------------------------------------------------------

Mouse models have served as a useful tool for characterizing the biochemical and *in vivo* functions of genes. However, when used to model human diseases, the extent to which findings from mouse genetic models translate to humans has gained limited success. Importantly, using a systems biology approach, previous studies have revealed differences between mouse and human ([@bib51], [@bib73], [@bib62]). Our recent study identified conserved and diversified gene signatures from the comparison of human and mouse transcriptomes during Th17 cell polarization ([@bib82]). To further establish the level of dissimilarity, we made direct comparison with data from a recently published proteomics dataset from mouse Th17 cells cultured for 72 hr ([@bib53]). The proteome profiles of CD4+ T cells 72 hr after TCR activation and Th17 polarization were compared using the aforementioned mouse data and the human data from the current study.

Comparison of the proteins detected in human (5,917 proteins) and mouse (3,731 proteins) revealed high degree of overall overlap as homologs for almost 85% of the mouse proteins were also detected in human ([Figure 6](#fig6){ref-type="fig"}A, [Table S6](#mmc7){ref-type="supplementary-material"}). To make the comparison of the differentially regulated proteins more comprehensive, we used a threshold of FDR 0.1 (used in [@bib53]) in both datasets to define the DE proteins. In agreement with our previous study ([@bib82]), there was very limited overlap between the proteins differentially regulated between Th17 and Th0 cells, respectively, in human and mouse. Of the 758 and 397 proteins differentially regulated at 72 hr between Th17 and Th0 in mouse and in human, respectively, only 33 proteins were detected as differentially regulated in a similar fashion in human and mouse ([Figure 6](#fig6){ref-type="fig"}B; [Table S6](#mmc7){ref-type="supplementary-material"}). Moreover, 18 proteins showed regulation in expression the opposite direction in human and mouse.Figure 6Comparison of Differential Regulation between Th17 and Th0 at 72 hr in Human and Mouse(A--D) Venn diagrams demonstrating (A) the total number of common and unique detections in human and mouse proteomics data and (B) the number of common and unique differentially regulated proteins detected. The numbers of differentially regulated proteins behaving in the similar or opposite fashion is shown in the overlap. Differentially regulated proteins refer to those proteins detected as DE or only in one condition. The *Z* score standardized expression levels of the commonly detected differentially regulated proteins regulated (C) similarly or (D) in an opposite fashion in human and mouse.(E) Immunoblot validations of SATB1 and CD44 expression in human and mouse during Th17 cell polarization. Blots show the protein extracts from the Th0 and Th17 cells at 72 hr. A representative blot from three biological replicates is shown.(F) The logarithmic fold changes (logFC) of all the common detections in human and mouse. The DE proteins detected as DE also in mouse are marked with black, and those uniquely DE in humans are marked with red. The Pearson correlation coefficient for the logFCs of all the common detections was 0.102 (p value \< 0.001, n = 3,143), 0.304 (p value = 0.46, n = 8) with the common DE proteins detected, and 0.34 (p = 0.04, n = 73) for the DE findings unique to humans among the common detections.(G) The logFCs and identities of the 25 most up- and downregulated DE proteins in humans and mouse. The common detection is marked with \*\*. Proteins detected as DE in the other species but not among the 25 most up- and downregulated are marked with \*. Mouse genes corresponding to mouse proteins are transformed as orthologous human genes for comparison using Ensembl BioMart. Black color in the heatmaps stands for undetected/missing value.

Of the 33 proteins whose expression was regulated similarly in human and mouse ([Figure 6](#fig6){ref-type="fig"}B), 15 and 18 proteins were upregulated and downregulated, respectively, in Th17 conditions at 72 hr ([Figure 6](#fig6){ref-type="fig"}C). Further analysis of the 18 proteins that showed opposite expression patterns between Th17 and Th0 in the two species at 72 hr revealed eight proteins (including DDX58, CD44, REL, and PRDX4) with upregulation in human and downregulation in mouse. The 10 proteins differentially upregulated in mouse and downregulated in human Th17 conditions included IL16, SATB1, LEF1, and LPXN ([Figure 6](#fig6){ref-type="fig"}D). The relative changes in expression of CD44 and SATB1 were validated both in human and mouse with western blot. RORyt and BATF proteins were used as polarization markers for mouse Th17 cell differentiation ([Figure S5](#mmc1){ref-type="supplementary-material"}A). The immunoblot results demonstrated that the expression of these proteins was consistent with comparative analysis of quantitative proteomic data ([Figures 6](#fig6){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}B).

SATB1, a chromatin organizer and transcription factor, is known to control the expression of a large number of genes involved in T cell development, activation, and differentiation both in mouse and human ([@bib4], [@bib2], [@bib58], [@bib15]). Both in mouse and human, SATB1 regulates Th2 cell differentiation by directly controlling the expression of its target genes and mediates topological looping of the transcriptionally active chromatin to the Th2 cytokine locus ([@bib16], [@bib58]). FOXP3-mediated inhibition of SATB1 expression in human Treg cells is critical for their suppressive function as well as repression of genes for effector T cell differentiation ([@bib10]). Although the expression of SATB1 is conserved between Th2 and Treg cells, its opposite expression profile in human and mouse in Th17 cells suggests a different role in driving Th17 cell differentiation.

CD44 is a transmembrane glycoprotein with diverse functions in a variety of cell types ([@bib6]). In T cells, CD44 deficiency in Th1 cells leads to compromised cell survival and abrogated generation of cellular memory to viral infection ([@bib5]). CD44 is also required for the suppressive function of Treg cells by promoting persistent expression of FOXP3 and suppressive cytokines TGF-α1 and IL-10 ([@bib13]). Mice lacking *Cd44* gene have an increased secretion of IL-17 and severe experimental autoimmune encephalomyelitis (EAE) disease score ([@bib31]). However, a contrasting study revealed CD44 deletion to downregulate Th1/Th17 differentiation, promote Th2 differentiation, and ameliorate clinical EAE disease score ([@bib34]). Because, the majority of the understanding on the regulation and functions of CD44 in T cells have come from studies in mouse, the opposite expression profile of CD44 in human and mouse Th17 cells deserves further studies to clarify its function in humans. Our results suggest these proteins to have different roles in polarizing Th17 cells in human and mouse. Moreover, the vast majority of the proteins detected as DE between Th17 and Th0 at 72 hr after the initiation of Th17 polarization in human were not detected as DE in mouse, and vice versa. Furthermore, we detected a number of proteins in one species, but not in the other. For instance, the proteins CEP250, ANXA1, ALCAM, OAS3, and BASP1 were not detected at all in Th17 cells in mouse, whereas LY9 and CDKN1B were not detected in human Th17 cells. Moreover, the proteins, BACH2, SH2D2A, FOXO1, DLGAP4, SLC4A7, TMLHE, LDLRAP1, CPD, and KDM3B were not detected in mouse Th0 condition.

To address the level of conservation (similarity) of protein signatures between human and mouse, Pearson correlation coefficients were calculated for logarithmic fold changes (Th17 versus Th0) of the proteins detected in human and mouse. Overall, the analysis revealed very little correlation (R^2^ = 0.102, p value \< 0.001, n = 3,143), although it was somewhat better for the proteins that were DE in both human and mouse (R^2^ = 0.304, p value = 0.46, n = 8) and for the DE proteins unique to human among the common detections (R^2^ = 0.34, p = 0.04, n = 73) ([Figure 6](#fig6){ref-type="fig"}F, [Table S6](#mmc7){ref-type="supplementary-material"}). Upon examination of 25 most up- and downregulated DE proteins in human and mouse, we found only IL2RG detected in both species. In addition, SATB1 (human) and RBPJ (mouse) were also detected as DE in both species, but not among the 25 most up- and downregulated in one of the species ([Figure 6](#fig6){ref-type="fig"}G, [Table S6](#mmc7){ref-type="supplementary-material"}). Overall, our analysis identified a very low degree of similarities in DE protein signatures between human and mouse, as well as a number of proteins even with opposite expression patterns, underscoring why studies using mouse genetic models have limited success in recapitulating the results in humans.

Repression of SATB1 Expression Contributes to Human Th17 Cell Differentiation {#sec2.7}
-----------------------------------------------------------------------------

The expression of SATB1 in distinct Th and Treg cells is shown to be conserved between human and mouse ([@bib66], [@bib2], [@bib10]). SATB1 expression has been previously reported to be upregulated in mouse Th17 cells ([@bib20], [@bib53]). However, we found SATB1 transcription to be downregulated during human Th17 cell differentiation ([@bib81], [@bib82]). This observation was further complemented by the findings, both at transcript and protein levels from our current transcriptomics and proteomics data and further validated by real-time quantitative PCR analysis and western blot analysis ([Figures 4](#fig4){ref-type="fig"}A, [6](#fig6){ref-type="fig"}D, 6E, [7](#fig7){ref-type="fig"}A, and 7B; [Table S4](#mmc5){ref-type="supplementary-material"}). To examine the role of SATB1 in human Th17 cells, RNAi was used to silence its expression. Introduction of SATB1-specific small interfering RNA (siRNA) (siSATB1) in differentiating Th17 cells resulted in a significant decrease in the expression of SATB1 both at mRNA and protein levels when compared with non-targeting scramble siRNA ([Figures 7](#fig7){ref-type="fig"}C, 7D, and [S5](#mmc1){ref-type="supplementary-material"}C). SATB1 silencing in Th17 cells led to increased transcription of marker cytokines *IL-17A* and *IL-17F* genes as well as the secretion of IL-17A cytokine ([Figures 7](#fig7){ref-type="fig"}E and 7F). In addition, depletion of SATB1 resulted in the increased expression of Th17-specific chemokine receptor, CCR6 ([Figure 7](#fig7){ref-type="fig"}G). Overall, depletion of SATB1 results in increased expression of the Th17 cell signature genes suggesting it acts as a negative regulator of Th17 cell differentiation in humans.Figure 7SATB1 Is a Negative Regulator of Human Th17 Cell DifferentiationThe mRNA expression profile of SATB1 in Th0 and Th17 cells at 48 and 72 hr after cell activation (A). Western blot analysis of SATB1 expression in Th0 and Th17 cells at 48 and 72hr after cell activation (B). The RNA interference (RNAi)-mediated knockdown of SATB1 at 24 hr post-Th17 cell polarization using specific siRNAs. Scramble siRNA (SCR) was used as a negative control. Silencing of SATB1 at mRNA (C) and protein (D) level was measured. Effect of SATB1 knockdown on IL-17A and IL-17F mRNA levels (E) by real-time TaqMan PCR analysis and on IL-17A protein secretion (F) was quantitated by ELISA assay from SATB1 siRNA nucleofected Th17 cells relative to NT-siRNA at 72 hr post-initiation of Th17 polarization. CCR6 surface expression detected by flow cytometry was measured (G) from SATB1 siRNA nucleofected Th17 cells relative to NT-siRNA at 72 hr post-initiation of Th17 polarization. Data are representative of 3--5 independent experiments. Error bars represent standard deviation values across biological replicates (n = 3--5; \*p \< 0.05, \*\*p \< 0.01 for Th0 versus Th17 and SCR versus siSATB1; two-tailed t-test analysis).

Discussion {#sec3}
==========

The role of Th17 cells has been established in the pathogenesis of inflammatory and autoimmune diseases and cancer ([@bib33], [@bib7]). Since their discovery a decade ago, most studies have used mouse model to identify key regulators and molecular mechanisms driving Th17 cell development and function. However, the molecular mechanisms and signaling pathways that regulate human Th17 cell differentiation remain largely unclear. Our understanding of the human Th17 cell development and functions rely on studies of individual gene function or studies utilizing genome-wide transcriptional profiling to gain a holistic systems view ([@bib81], [@bib82], [@bib32]). However, genome-wide transcriptome analysis only describes the general characteristics of molecular changes ([@bib74]) and does not necessarily reflect the specific phenotypic changes, which are controlled at the protein level.

In the recent years, global proteomic approaches have been adapted for the global analysis of complex proteomes in several distinct human immune cell types, including B and plasma cells ([@bib67]), macrophages and dendritic cells ([@bib8], [@bib26], [@bib89]), neutrophils ([@bib80]), resting T cells ([@bib37]) cytotoxic T cells (CTL) ([@bib39], [@bib1]), natural killer T cells ([@bib69]), Th1 and Th2 cells ([@bib29]), and Treg cells ([@bib42], [@bib25], [@bib23], [@bib70]). In addition, a recent study describing the proteomes of Th1/Th17 clones derived from the gut biopsies of the patient with Crohn disease identified protein signatures of "mixed" Th1/Th17 phenotypes using MS-based protein identification and quantification ([@bib65]).

In the present study, we have used a label-free MS approach to reveal qualitative and quantitative proteomic differences between Th0 and Th17 cells during early stages of cellular stimulation and differentiation from naive CD4+ T cell subsets isolated from the umbilical cord blood. To understand the dynamics of protein expression changes during early stages of Th17 cell differentiation, we characterized proteome changes at 24 and 72 hr after initiation of the Th17 cell polarization. Despite the fact that the vast majority of the proteome is shared between TCR-activated cells (Th0) and cells primed for Th17 cell polarization at this early stage, our analyses demonstrated significant temporal and lineage-specific changes in the proteome. Overall, we observed clear differences in protein abundance associated with Th17 cell polarization.

Our analysis of the cellular proteome during early Th17 cell differentiation identified the differential expression of 291 proteins. The detected DE proteins included key protein markers used to characterize early differentiating human Th17 cells, such as cell surface markers (CCR4, CTLA-4, ICOS, and PDCD1), cytokines (CCL20 and TNF-α), and nuclear proteins (RUNX1, SIRT1, AHR, RBPJ, JUNB, REL, and FOSL2). These findings support the overall strength of the proteomic data generated and the MS-based approach implemented in this study. In addition, we discovered a number of additional proteins with significant differential expression between Th17 and Th0 cells that might have functional effects on Th17 development and function. Such examples are two glycosylphosphatidylinositol (GPI)-anchored cell surface glycoproteins, namely, semaphorin 7A (SEMA7A; also known as CD108) and CD109. SEMA7A is a negative regulator of T cell responses ([@bib24]). It has important roles in inflammatory and autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and colitis ([@bib77], [@bib40], [@bib35]). Yet, the molecular mechanism of how SEMA7A regulates differentiation and functioning of Th17 cells is not known. Likewise, CD109 is a co-receptor for TGF-β that negatively regulates TGF-β signaling. CD109 does this by coupling with caveolin-1, which mediates internalization and degradation of TGF-β receptors via receptor-mediated endocytosis ([@bib11]) or via regulating SMAD7/Smurf2-mediated degradation of TGFBR1 ([@bib12]). The regulation of TGF-β signaling contributes to the development of Th17 cells. At lower concentrations, TGF-β supports Th17 differentiation, and at higher concentrations, it promotes the differentiation of Treg cells. Besides its role in controlling TGF-β signaling, in human keratinocytes CD109 amplifies the activation of STAT3 ([@bib44]), a transcription factor also required for Th17 development.

Interestingly, FURIN, found to be upregulated in Th17 cells in our analysis, is a pro-protein convertase enzyme involved in the processing of CD109 into the 180-kDa secreted form and 25-kDa GPI-anchored form, suggesting that FURIN participates in regulating CD109-mediated molecular functions. In mouse, the deficiency of FURIN in T cells causes T cell expansion/activation, impaired production of TGF-β1, and breakdown of the peripheral tolerance ([@bib61]). However, the molecular mechanisms by which FURIN regulates Th17 cell development are still unclear. Consistent with these findings, Th17-specific upregulation of FURIN and CD109 in our analysis suggests that they may participate in controlling the development and function of Th17 cells via an overlapping pathway.

A number of proteins involved in the regulation of nuclear structure organization or function were found to be differentially upregulated (e.g., LMNA, MYOF, BASP1, IRF7, BHLHA15, PARP9, PARP10, PARP14, and CDK6) or downregulated (e.g., ELF1, ACTBL2, CHURC, CNBP, SATB1, IRF8, and IKZF1) in Th17 cells. These observations suggest an important role of these proteins in influencing nuclear architecture and function, which are active parts of regulating chromatin structure or transcription. In mouse, IRF8 has been shown to inhibit Th17 differentiation where IRF8 physically interacts with RORγt, and suppresses *Il-17a* transcription ([@bib60]). The reduced expression of IRF8 in human Th17 cells when compared with Th0 cells further supports its role as a negative regulator of Th17 cell differentiation. The expression of IKZF1 (Ikaros) was downregulated in Th17 cells across all replicates. However, a study of Ikaros knockout mouse has shown that IKZF1 positively regulates the development and function of Th17 cells ([@bib88]). The role of IKZF1 in the human system has not been reported. Further studies are needed to uncover the mechanisms and functions of these proteins in the regulation of Th17 cell development.

The mapping of protein-protein interactions is important in understanding the molecular mechanisms regulating cellular processes. The STRING analysis showed a highly cohesive protein-protein network and revealed abundant functional interactions between the proteins involving distinct GO biological processes. The majority of the protein-protein interactions in the network were related to the regulation of cellular metabolic processes with a number of the interactions involving proteins of lipid metabolic process. The role of a few proteins (e.g., FADS2 and FASN, ACC1, AHR, and HSD17B7) of the lipid metabolism pathway from our network has been recently reported to regulate Th17 function ([@bib9], [@bib38], [@bib68], [@bib86], [@bib75]).

Among the validated Th17-regulated proteins, JUNB, SATB1, SMAD3, STAT4, ATF3, and ETS1 have previously been shown to have functional roles either in the context of Th17 cells or other Th cell subsets. In addition, RUNX1, ATP1B1, KDSR, LMNA, VDR, and BASP1 were validated at the protein level also in our previous report ([@bib81]). The STAT3-dependent expression of JUNB and its role in positively regulating Th17 cell differentiation have been recently described in mouse model ([@bib17]). Furthermore, SMAD3 ([@bib48]) and ETS1 ([@bib54]) negatively regulate the murine Th17 cell function. STAT4 is a major regulator of Th1 cell differentiation and function, and is a critical component in maintaining the balance between Th17 and Treg cells under disease states ([@bib90]). Importantly, some of the validated proteins, including BASP1, LMNA, IRF7, ATF3, ACSL4, FHOD1, SMTN, ATP1B1, RDX, PALLD, and OASL have previously been poorly characterized or not reported to regulate Th17 cell differentiation and function and are hence candidates for functional follow-up studies. For example, we have previously reported that ATF3 directly regulates the human IFN-γ expression and promotes Th1 differentiation ([@bib30]). However, the role of ATF3 in regulating the differentiation and function of human Th17 cells remains to be studied. In a mouse model, IRF7 silencing in resting CD4+ cells resulted in the increased secretion of Th17-associated cytokines (e.g., IL-17A, IL-17F, IL-21, IL-22, and IL-9), suggesting that IRF7 is a negative regulator of the Th17 response ([@bib79]). However, the molecular mechanisms responsible for the expression of IRF7 and how it regulates human Th17 cell polarization are still unclear.

Recent studies have addressed the role of lipid metabolism in regulating Th17 cell differentiation and function ([@bib9], [@bib86], [@bib75], [@bib93]). As an enzyme involved in lipid metabolic pathways, ACSL4 is an interesting candidate for further studies on regulation of Th17 cell differentiation. Other candidates of interest, although not related to lipid metabolism, are FHOD1, RDX, and SMTN. These structural proteins regulate cell migration and contraction ([@bib57], [@bib71]). However, their role in Th17 cell differentiation and function remains undetermined.

A comparison between the proteomic and transcriptomic profiles can provide valuable insight into the relationship between mRNA and protein expression that may not be feasible to achieve by separate analysis of either dataset alone ([@bib56], [@bib89]). To that end, we compared the current proteomics data with RNA-seq data from the same samples processed for MS-based proteome analysis. Almost 95% of the proteins detected by LFQ analysis had transcripts for the corresponding protein-coding genes and displayed good correlation in their relative abundance versus Th0 (0.519) ([Figure 5](#fig5){ref-type="fig"}B) consistent with the recent studies on other cells including human Treg cells ([@bib87], [@bib23], [@bib70]). The DE proteins showed even improved correlation (0.819). However, we detected 21 proteins DE in a Th17-specific manner that were not observed at the transcriptome level. However, of these 21 DE proteins, only two proteins ITM2B and COX7A2L were also found to be DE and downregulated in Th17 condition in our reanalysis of the mouse proteomics data from [@bib53]. Moreover, they reported that the expression of ITM2B was DE in mouse Th17 transcriptomics analysis with opposite expression profile compared with their protein data (i.e., downregulated at the RNA level and upregulated at the protein level when Th17 polarized cells were compared with activated cells). COX7A2L was found to be downregulated in mouse both at the transcript and protein levels. The expression of CEP250 was observed as DE and downregulated in human proteomics data, whereas it was detected only in the Th0 condition in mouse proteomics data and not detected as DE in mouse transcriptomics data. Thus based on our analysis it appears that the majority of these 21 DE proteins are uniquely post-transcriptionally regulated in humans. To conclude, our study provides several candidate proteins whose roles in the regulation of Th17 differentiation and function are yet to be determined.

Comparative analysis of transcriptional changes in human and mouse during immune cell differentiation, including Th17 cell specification, revealed a conserved signature between these species ([@bib73], [@bib82]). This includes a panel of potential therapeutic targets that are regulated in a similar fashion in human and mouse and thus suitable for follow-up studies in experimental *in vivo* mouse models. In this study, we complemented our previous study by comparing human and mouse proteomes, which demonstrated remarkable differences in the regulation of protein expression between human and mouse during Th17 cell priming. Interestingly, only 33 proteins were differentially regulated in a similar fashion, whereas 18 showed regulation to the opposite direction in human and mouse. Although consistent with our previous results comparing DE transcripts from human and mouse during Th17 cell differentiation ([@bib82]), the lack of overlap at the protein level is even more striking. Moreover, our results are in line with other recent reports, including those from the ImmGen consortium, suggesting inter-species differences in the cellular machinery due to the operations of conservation and diversification of the *trans*- and *cis*-regulatory programs ([@bib51], [@bib73]). Although the proteins regulated in a similar manner in human and mouse are good candidates for follow-up functional *in vivo* studies in experimental mouse models, further investigation on the proteins regulated in opposite manner among common DE proteins in human and mouse along with human-specific DE proteins is critical for understanding their role in regulating Th17 cell differentiation and function in humans.

The expression of SATB1 was downregulated in human Th17 cells when compared with Th0 cells, suggesting its role as a negative regulator of human Th17 cell differentiation. However, a previous mouse study reported that SATB1 positively regulates Th17 function by controlling the expression of key Th17-related genes including *Il-22, Il-17A* and *Il-17F, Il21, Il1R1,* and *Ccl20* ([@bib20]). Opposite regulation of this key chromatin organizer (i.e., SATB1) during early specification of human and mouse Th17 cells suggests fundamental differences in the process between the two species. Moreover, recently, conditional deletion of SATB1 in mouse showed impaired production of IL-17- and IFN-γ in pathogenic T cells, and the mouse were resistant to the induction of EAE, suggesting a role of SATB1 for the generation of pathogenic Th cells ([@bib3]). Using the RNAi approach, we showed that SATB1 knockdown induced an elevated expression of marker cytokines IL-17A and IL-17F and CCR6, a chemokine expressed on the surface of Th17 cells. This suggests SATB1 to be a negative regulator of Th17 cell priming. Further studies are required to gain insight into the molecular mechanisms through which SATB1 controls Th17 differentiation and function in humans.

In summary, our results revealed differences in the proteome of the cell types and time points studied and shed light on various perspectives of the early regulation of human Th17 cell priming. Beyond previous transcriptomics applications describing the regulatory programs that govern Th17 cell development and function in human and mouse, our study reports comprehensive proteomics data describing the initiation of human Th17 cell priming of naive CD4+ T cells derived from the umbilical cord blood. Hence, this study complements previous investigations to understand human Th17 cell priming. This study has resulted in the identification of a panel of proteins with unknown or poorly characterized functions in the context of Th17 development and function. We provide several previously unknown candidate proteins for further studies to reveal their influence on human Th17 specification and immunomodulatory and therapeutic potential for Th17-mediated immune diseases.

Limitations of the Study {#sec3.1}
------------------------

This study describes the global cellular proteomic landscape during early human Th17 cell differentiation. However, the current data only represents unfractionated cellular lysates. The fractionation of the cellular compartments could have provided further insight into the differentiation process. Furthermore, mechanistic follow-up studies on key findings reported here are required and are interesting targets for future studies. Our comparison of human to mouse Th17 proteomics data showed very limited overlap. It would be important to consider the kinetics of the process in the mouse---here we compared our data with data from a reported parallel study in mouse, where only one time point had been analyzed. It will be important to functionally validate in the mouse system the few findings with consistent results in human. Understanding the molecular mechanisms of proteins regulated in a similar fashion in human and mouse is crucial for translational research.

Ethical Aspects {#sec3.2}
---------------

The usage of blood of unknown donors was approved by the Ethics Committee of the Hospital District of Southwest Finland. Experiments using animals\' cells were in accordance with the relevant University Animal Welfare guidelines.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Software Availability {#appsec1}
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The PRIDE accession number ([@bib84]) for the mass spectrometry proteomic profiling data presented in this paper is PXD008973. The selected reaction monitoring (SRM) validation data are available through PASSEL with the dataset identifier PASS01204. The RNAseq data from this study is submitted to the Gene Expression Omnibus (GEO) with identifier [GSE118974](ncbi-geo:GSE118974){#interref2000}.
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